ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 164

Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study

Massimo Radin1, Irene Cecchi2, Elena Rubini3, Anna Scotta4, Roberta Rolla5, Barbara Montaruli6, Patrizia Pergolini5, Giulio Mengozzi4, Elena Muccini4, Antonella Vaccarino7, Dario Roccatello8 and Savino Sciascia9, 1Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 2Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, 4University of Turin, Turin, Italy, 5University of Turin, Novara, Italy, 6Ospedale Mauriziano, Turin, Italy, 7Ospedale S. Giovanni Bosco, Turin, Italy, 8Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, 9Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Anticoagulation, Antiphospholipid antibodies, laboratory tests, multicenter study and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Correct interpretation of lupus anticoagulant (LA) tests is crucial for diagnosis of antiphospholipid syndrome (APS). However, testing patients during vitamin K antagonist (VKA) or other anticoagulant treatment remains a contentious issue and has been discouraged by official guidelines because of interpretational problems affecting the mixing test.

Methods:

We enrolled 60 patients who met one of the following inclusion criteria: 1) Fulfilled the diagnosis of thrombotic APS defined as per Sidney criteria; 2) Patients with thrombosis and suspected APS not completely fulfilling the laboratory criteria, as follows: a) and inconstant previous LA positivity; and/or b) low-medium titers aPL (defined as levels of aCL IgG/IgM or anti-β2GPI IgG/IgM 10-30 GPL/MPL aPL) with no LA positivity. aPL testing was performed in a blind fashion in 4 centers undergoing periodic external quality assessment.

Results:

 The mean age at was 50 years old (SD ±11) (F:M 71,7% : 28,3%). Forty-three patients (72%) had a confirmed diagnosis of thrombotic APS (arterial 58%; venous 56%), and 17 patients presented with thrombosis and inconstant LA positivity (N. 7; 41%) and/or with low-medium titers  (N. 10;59%). Categorical agreement for LA among the centers, as expressed by Cohen’s kappa coefficients, ranged between 0.41 and 0.60 (corresponding to moderate agreement). The correlation among quantitative results at the 4 sites for aPS/PT IgG was strong (Cohen’s kappa coefficients=0.81–1. Spearman rho 0.84). We observed 27 (45 % of the total) cases (15/20, 75% patients on VKA) in which LA results were discordant (as defined by lack of agreement in ≥3 laboratories) or inconclusive. Conversely, in those cases, we observed a good correlation for aPS/PT IgG testing (Cohen’s kappa coefficients=0.81–1, Spearman rho 0.86). aPS/PT testing showed an overall agreement of 83% (up to 90% in patients receiving VKA), providing an overall increase in test reproducibility of + 28% when compared to LA, becoming even more evident (+65%) when analyzing patients on VKA.  

Conclusion:

Despite the progress in the standardization of aPL testing, we observed up to 45% of discrepant results for LA, even higher in patients on VKA. Our findings highlight that some discordances in the reliability of LA testing still exist. The introduction of aPS/PT antibody testing into the diagnostic process of APS might represent a further diagnostic tool, especially when LA is not available or the results are uncertain.



Disclosure: M. Radin, None; I. Cecchi, None; E. Rubini, None; A. Scotta, None; R. Rolla, None; B. Montaruli, None; P. Pergolini, None; G. Mengozzi, None; E. Muccini, None; A. Vaccarino, None; D. Roccatello, None; S. Sciascia, None.

To cite this abstract in AMA style:

Radin M, Cecchi I, Rubini E, Scotta A, Rolla R, Montaruli B, Pergolini P, Mengozzi G, Muccini E, Vaccarino A, Roccatello D, Sciascia S. Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/reliability-of-lupus-anticoagulant-and-anti-phosphatidylserine-prothrombin-autoantibodies-in-antiphosphospholipid-syndrome-a-multicenter-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reliability-of-lupus-anticoagulant-and-anti-phosphatidylserine-prothrombin-autoantibodies-in-antiphosphospholipid-syndrome-a-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology